Immunotherapy in Metastatic Urothelial Carcinoma: Satellite Symposium

Urothelial carcinoma (UC) is the predominant histologic type of bladder cancer in the United States and Europe where it accounts for over 90% of all bladder cancers.11% of UC cases are locally advanced or metastatic (la/mUC) at diagnosis. Prognosis is extremely poor for la/mUC patients and less than 15% survive more than 5 years post diagnosis. Currently, metastatic UC is considered incurable and efforts to increase progression-free survival allowing for further sequential treatment in order to increase overall survival for these patients are progressing rapidly. After many years of dormancy, the treatment options for la/mUC patients underwent a paradigm shift as a new line of immunotherapy agents targeting programmed death-1 or programmed death-ligand 1 (PD-1/PD-L1) received full approval as second-line therapy by the FDA. In 2020, the role that ICIs played in urothelial cancer extended beyond the point of second-line treatment and a few have been recently approved as maintenance therapy options. The objective of this 90-minute virtual satellite symposium is to increase the knowledge and understanding that HCPs (targeting physicians, nurses, and physician assistants in the area of genitourinary oncology, and radiation oncology) have about the most recent ICI clinical trials for la/mUC patients and learn which patients stand to benefit the most specifically from ICI maintenance therapy.